On Friday, Shares of Kinder Morgan Inc (NYSE:KMI), gained 5.41% to $29.63.
Kinder Morgan, partner Tennessee Gas Pipeline Company (TGP) recently issued the following statement:
The Massachusetts Department of Public Utilities order finding that it has the authority to approve contracts reached by electric distribution companies (EDCs) to secure dedicated natural gas pipeline transportation capacity is an important step in ensuring that electric generators have reliable access to the fuel needed to generate electricity within the ISO-NE transmission grid.
By requiring that such contracts be subject to an open and transparent procurement process in order to win approval, the DPU’s order should also benefit consumers, as interstate pipeline companies serving the region compete to provide natural gas to electric generators across New England at the lowest cost.
“Tennessee Gas Pipeline supported the utilization of an open and transparent process during its participation in the DPU proceedings,” said Kimberly S. Watson, president of TGP. “TGP’s initiation last month of its open season for its innovative PowerServe transportation solution provides a competitive market alternative that will lead to lower consumer energy costs.”
Kinder Morgan, Inc. (KMI) is an energy infrastructure and energy company in North America. The Company operates through six segments: Natural Gas Pipelines, CO2, Terminals, Products Pipelines, Kinder Morgan Canada and Other. The Natural Gas Pipelines segment comprises interstate and intrastate pipelines and its liquefied natural gas (LNG) terminals. The CO2 business segment produces, transports, and markets CO2.
Shares of Bristol-Myers Squibb Co (NYSE:BMY), inclined 3.58% to $62.20, during its last trading session.
Shares of Bristol-Myers Squibb Company, rose by 3.3% in the past week and 8.6% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 2.24% and the outperformance improvements to 6.93% for the last 4 weeks.
The company shares have rallied 22.38% in the past 52 Weeks. On July 20, 2015 The shares registered one year high of $70.54 and one year low was seen on October 15, 2014 at $47.55. The 50-day moving average is $60.59 and the 200 day moving average is recorded at $64.77. S&P 500 has rallied 0.84% during the last 52-weeks.
In related news, Bristol-Myers Squibb Company, declared that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab), for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.
Recent declaration marks the first and only FDA approval of a Regimen of two Immuno-Oncology agents in cancer. This indication is approved under accelerated approval based on tumor response rate and durability of response.1 Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
The approval is based on data from the pivotal study, CheckMate -069, which was the first to report outcomes of the Opdivo + Yervoy Regimen in formerly untreated patients with unresectable or metastatic melanoma. Results from the trial demonstrated a statistically noteworthy(p<0.001) improvement in confirmed objective response rate – the study’s primary endpoint – in patients with BRAF wild-type melanoma treated with the Opdivo + Yervoy Regimen [60% (95% CI: 48-71; p<0.001)] contrast to those treated with Yervoy monotherapy [11% (95% CI: 3-25)]. Complete responses were seen in 17% of patients. Partial responses were seen in 43% of the Regimen group and 11% of the Yervoy monotherapy group. The Opdivo + Yervoy Regimen demonstrated a 60% reduction in the risk of progression vs. Yervoy alone (HR=0.40; 95% CI: 0.22-0.71; p<0.002). Median PFS was 8.9 months with the Regimen (95% CI: 7.0, NA) and 4.7 months with Yervoy alone (95% CI: 2.8-5.3).1 This trial provides clinical rationale for targeting the immune system with two Immuno-Oncology agents in metastatic melanoma.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession.
Shares of MGM Resorts International (NYSE:MGM), inclined 6.00% to $19.79, during its last trading session.
On Friday, the shares opened for trading at $19.02 and hit $19.91 on the upside , eventually ending the session at $19.79, with a gain of 6% or 1.12 points. The heightened volatility saw the trading volume jump to 10,626,205 shares. The 52-week high of the share price is $23.7 and the company has a market cap of $11,144 million. The 52-week low of the share price is at $16.84 .
In related news, MGM Resorts International, has been named one of America’s top 100 most reputable companies for corporate social responsibility (CSR), according to research by Reputation Institute, a leading global source on corporate reputation.
Reputation Institute’s top 100 list is derived from data collected by the 2015 U.S. CSR RepTrak®, a public survey examining the perceptions of companies by the U.S. general public. Involving more than 55,000 interviews during this year’s first quarter, U.S. CSR RepTrak® measured companies according to three dimensions: citizenship, workplace, and governance.
“Consumers want to engage with companies that are good corporate citizens,” said Brad Hecht, Chief Research Officer at Reputation Institute. “Companies with high CSR scores in our research can point to a demonstrated track record of ethical behavior and leadership.”
Among the other companies named to Reputation Institute’s list comprise: Google, Levi Strauss & Co., Panera Bread and Starbucks. MGM Resorts is one of a few companies in the hospitality industry to make the list.
MGM Resorts International is a holding company. Through its wholly owned auxiliaries, the Company owns and operates casino resorts. The Company operates in two segments: wholly owned domestic resorts and MGM China. The wholly owned domestic resorts segment comprises non-gaming operations, counting hotel, food and beverage, entertainment and other non-gaming amenities. Its casino operations feature a variety of table games, and race and sports book wagering. It operates over 15 wholly owned resorts in the United States.
Finally, Texas Instruments Incorporated (NASDAQ:TXN), ended its last trade with 0.68% gain, and closed at $48.77.
Texas Instruments (NASDAQ:TXN) has earned an “A+” credit rating from Morningstar. The research firm’s “A+” rating suggests that the company is a low default risk. They also gave their stock a four star rating.
In related news, Delivering optimal battery life while reducing power consumption, Texas Instruments (TI) (TXN) recently introduced a highly integrated battery administration solution presenting the industry’s lowest quiescent current (Iq) at 700-nA with the buck converter, operating at 1.8V. The bq25120 features a linear charger, configurable LDO, load switch, buck converter, pushbutton control and battery voltage monitor all in one. The solution supports batteries from 3.6-V to 4.65-V, and fast charge currents from 5-mA to 300-mA, allowing wearables and industrial Internet of Things (IoT) applications to always be on without draining the battery.
Texas Instruments Incorporated designs, makes and sells semiconductors to electronics designers and manufacturers across the world. The Company operates through two segments: Analog and Embedded Processing. The Company’s Analog segment comprises the following product lines: High Volume Analog & Logic, Power Administration, High Performance Analog and Silicon Valley Analog.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
